Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT00003475 Recruiting - Clinical trials for Brain and Central Nervous System Tumors

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

Start date: February 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with primary malignant brain tumors.

NCT ID: NCT00003470 Recruiting - Clinical trials for Brain and Central Nervous System Tumors

Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

Start date: March 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with anaplastic astrocytoma that has not responded to previous treatment.

NCT ID: NCT00003469 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System

Start date: February 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating children with rhabdoid tumor of the central nervous system.

NCT ID: NCT00003467 Completed - Clinical trials for Brain and Central Nervous System Tumors

Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma

Start date: January 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.

NCT ID: NCT00003466 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Progressive Low-Grade Glioma

Start date: March 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with progressive low-grade glioma.

NCT ID: NCT00003465 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

Start date: March 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with anaplastic oligodendroglioma.

NCT ID: NCT00003464 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme

Start date: September 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed primary malignant glioblastoma multiforme.

NCT ID: NCT00003463 Completed - Clinical trials for Brain and Central Nervous System Tumors

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

Start date: July 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.

NCT ID: NCT00003462 Completed - Clinical trials for Brain and Central Nervous System Tumors

Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors

Start date: April 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs into the thin space between the lining of the spinal cord and brain may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of intrathecal busulfan in treating patients with recurrent, refractory, or metastatic leptomeningeal tumors.

NCT ID: NCT00003461 Completed - Metastatic Cancer Clinical Trials

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

Start date: February 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients with primary or metastatic brain tumors.